A former scientist at Google's DeepMind who co-developed the AlphaFold2 protein prediction platform, Dr Simon Kohl, has launched his own venture applying artificial intelligence to drug discovery.

Presentations highlight cutting-edge research in mitochondrial and neurodegeneration medicine, neurodegeneration, ...

Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with traditional biology research to accelerate drug discovery, today announced ...

Another factor that may be contributing to the decline in publishing by industry medicinal chemists is the fact that ...

Fill out the form below and we'll send your colleague an invitation to the "Advances in Target-Based Drug Discovery: A Spotlight on Optical Biosensors" event. Optical biosensors are transforming how ...

Momentum Biotechnologies ("Momentum"), a contract research organization specializing in mass spectrometry-based drug discovery and proteomics, announced today the appointment of two new members to its ...

Tadaaki Taniguchi, M.D., Ph.D., Chief Research & Development Officer, Astellas | Astellas’ Chief R&D Officer, Tadaaki ...

AMP-945 – discovered at the former Cancer Therapeutics Cooperative Research Centre – works by suppressing a bodily agent ...

Hitchings proposed another way forward—a rational, scientific approach to drug discovery based on knowledge of a biological target. He hypothesized that scientists could inhibit pathogen cells ...

As founder of HUYA Bioscience International, Lady Mireille Gillings built a pioneering model to accelerate the global development of novel biopharmaceutical therapies originating in China.

The term "digital twins" has its origins in engineering and computer science ... or a drug manufacturing process. Digital twins have tremendous potential to revolutionise drug discovery and ...